Gene Therapy for Leukemia and Lymphoma

  • Xiaopei Huang
  • Yiping Yang
Part of the Molecular Pathology Library book series (MPLB, volume 4)


With the advancement of knowledge in immunology and virology, technological improvement in the transduction efficiency of existing viral vectors, and the development of new viral vectors in the past two decades, gene therapy targeting diseases at a molecular level has emerged as an exciting and promising strategy for treating hematolymphoid malignancies. Gene therapy is aimed to correct disease processes by introducing a functional gene into target cells to restore or modify cellular functions. Unlike conventional therapies for treating cancers, gene therapy, in theory, could deliver precise, malignancy-specific treatment with minimal side effects on normal cells and biological processes. For many patients with hematolymphoid malignancies who cannot benefit from the therapies available today, gene therapy may hold the promise of future treatment.


Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Costimulatory Molecule Anaplastic Large Cell Lymphoma Chronic Lymphocytic Leukemia Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Wierda WG, Kipps TJ. Gene therapy and active immune therapy of hematologic malignancies. Best Pract Res Clin Haematol. 2007;20:557–568.CrossRefPubMedGoogle Scholar
  2. 2.
    Knipe DM, Howley PM, eds. Fields Virology. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.Google Scholar
  3. 3.
    Naldini L et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263–267.CrossRefPubMedGoogle Scholar
  4. 4.
    Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer. 2003;3:477–488.CrossRefPubMedGoogle Scholar
  5. 5.
    Lewinski MK, Bushman FD. Retroviral DNA integration – mechanism and consequences. Adv Genet. 2005;55:147–181.CrossRefPubMedGoogle Scholar
  6. 6.
    Levine AJ. p53, the cellular gatekeeper for growth and division. Cell. 1997;88:323–331.CrossRefPubMedGoogle Scholar
  7. 7.
    Meeker TC, Lay LT, Wroblewski JM, Turturro F, Li Z, Seth P. Adenoviral vectors efficiently target cell lines derived from selected lymphocytic malignancies, including anaplastic large cell lymphoma and Hodgkin’s disease. Clin Cancer Res. 1997;3:357–364.PubMedGoogle Scholar
  8. 8.
    Turturro F, Seth P, Link CJ Jr. In vitro adenoviral vector p53-mediated transduction and killing correlates with expression of coxsackie-adenovirus receptor and alpha(nu)beta5 integrin in SUDHL-1 cells derived from anaplastic large-cell lymphoma. Clin Cancer Res. 2000;6:185–192.PubMedGoogle Scholar
  9. 9.
    Marini FC 3rd, Yu Q, Wickham T, Kovesdi I, Andreeff M. Adenovirus as a gene therapy vector for hematopoietic cells. Cancer Gene Ther. 2000;7:816–825.CrossRefPubMedGoogle Scholar
  10. 10.
    Turturro F, Heineke HL, Drevyanko TF, Link CJ Jr, Seth P. Adenovirus-p53-mediated gene therapy of anaplastic large cell lymphoma with t(2;5) in a nude mouse model. Gene Ther. 2000;7:930–933.CrossRefPubMedGoogle Scholar
  11. 11.
    McNeish IA, Bell SJ, Lemoine NR. Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. Gene Ther. 2004;11:497–503.CrossRefPubMedGoogle Scholar
  12. 12.
    Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol. 2003;4:415–422.CrossRefPubMedGoogle Scholar
  13. 13.
    Buller RE et al. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer. Cancer Gene Ther. 2002;9:553–566.CrossRefPubMedGoogle Scholar
  14. 14.
    Schuler M et al. Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J Clin Oncol. 2001;19:1750–1758.PubMedGoogle Scholar
  15. 15.
    Kuball J et al. Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol. 2002;20:957–965.CrossRefPubMedGoogle Scholar
  16. 16.
    Pagliaro LC et al. Repeated intravesical instillations of an adenoviral vector in patients with locally advanced bladder cancer: a phase I study of p53 gene therapy. J Clin Oncol. 2003;21:2247–2253.CrossRefPubMedGoogle Scholar
  17. 17.
    Lang FF et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol. 2003;21:2508–2518.CrossRefPubMedGoogle Scholar
  18. 18.
    Zhang X et al. Adenoviral-mediated retinoblastoma 94 produces rapid telomere erosion, chromosomal crisis, and caspase-dependent apoptosis in bladder cancer and immortalized human urothelial cells but not in normal urothelial cells. Cancer Res. 2003;63:760–765.PubMedGoogle Scholar
  19. 19.
    Li D et al. The role of adenovirus-mediated retinoblastoma 94 in the treatment of head and neck cancer. Cancer Res. 2002;62:4637–4644.PubMedGoogle Scholar
  20. 20.
    Turturro F, Arnold MD, Frist AY, Seth P. Effects of adenovirus-mediated expression of p27Kip1, p21Waf1 and p16INK4A in cell lines derived from t(2;5) anaplastic large cell lymphoma and Hodgkin’s disease. Leuk Lymphoma. 2002;43:1323–1328.CrossRefPubMedGoogle Scholar
  21. 21.
    Dilber MS, Gahrton G. Suicide gene therapy: possible applications in haematopoietic disorders. J Intern Med. 2001;249:359–367.CrossRefPubMedGoogle Scholar
  22. 22.
    Freeman SM et al. The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 1993;53:5274–5283.PubMedGoogle Scholar
  23. 23.
    Elliott G, O’Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell. 1997;88:223–233.CrossRefPubMedGoogle Scholar
  24. 24.
    Dilber MS et al. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther. 1999;6:12–21.CrossRefPubMedGoogle Scholar
  25. 25.
    Bonini C et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science. 1997;276:1719–1724.CrossRefPubMedGoogle Scholar
  26. 26.
    Burt RK et al. Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. Exp Hematol. 2003;31:903–910.CrossRefPubMedGoogle Scholar
  27. 27.
    Qasim W, Gaspar HB, Thrasher AJ. T cell suicide gene therapy to aid haematopoietic stem cell transplantation. Curr Gene Ther. 2005;5:121–132.PubMedGoogle Scholar
  28. 28.
    Thomis DC et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood. 2001;97:1249–1257.CrossRefPubMedGoogle Scholar
  29. 29.
    Hannon GJ. RNA interference. Nature. 2002;418:244–251.CrossRefPubMedGoogle Scholar
  30. 30.
    Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 2001;409:363–366.CrossRefPubMedGoogle Scholar
  31. 31.
    Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343–3356.PubMedGoogle Scholar
  32. 32.
    Wilda M, Fuchs U, Wossmann W, Borkhardt A. Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi). Oncogene. 2002;21:5716–5724.CrossRefPubMedGoogle Scholar
  33. 33.
    Scherr M et al. Specific inhibition of bcr-abl gene expression by small interfering RNA. Blood. 2003;101:1566–1569.CrossRefPubMedGoogle Scholar
  34. 34.
    Westendorf JJ et al. The t(8;21) fusion product, AML-1-ETO, associates with C/EBP-alpha, inhibits C/EBP-alpha-dependent transcription, and blocks granulocytic differentiation. Mol Cell Biol. 1998;18:322–333.PubMedGoogle Scholar
  35. 35.
    Pabst T et al. AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat Med. 2001;7:444–451.CrossRefPubMedGoogle Scholar
  36. 36.
    Jakubowiak A et al. Inhibition of the transforming growth factor beta 1 signaling pathway by the AML1/ETO leukemia-associated fusion protein. J Biol Chem. 2000;275:40282–40287.CrossRefPubMedGoogle Scholar
  37. 37.
    Vangala RK et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood. 2003;101:270–277.CrossRefPubMedGoogle Scholar
  38. 38.
    Heidenreich O et al. AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells. Blood. 2003;101:3157–3163.CrossRefPubMedGoogle Scholar
  39. 39.
    Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene. 2001;20:5623–5637.CrossRefPubMedGoogle Scholar
  40. 40.
    Drexler HG et al. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia. 2000;14:1533–1559.CrossRefPubMedGoogle Scholar
  41. 41.
    Damm-Welk C, Fuchs U, Wossmann W, Borkhardt A. Targeting oncogenic fusion genes in leukemias and lymphomas by RNA interference. Semin Cancer Biol. 2003;13:283–292.CrossRefPubMedGoogle Scholar
  42. 42.
    Brenner MK. Gene transfer and the treatment of haematological malignancy. J Intern Med. 2001;249:345–358.CrossRefPubMedGoogle Scholar
  43. 43.
    Bubenik J et al. Gene therapy of cancer: use of IL-2 gene transfer and kinetics of local T and NK cell subsets. Anticancer Res. 1993;13:1457–1460.PubMedGoogle Scholar
  44. 44.
    Simova J, Bubenik J, Jandlova T, Indrova M. Irradiated IL-2 gene-modified plasmacytoma vaccines are more efficient than live vaccines. Int J Oncol. 1998;12:1195–1198.PubMedGoogle Scholar
  45. 45.
    Dilloo D et al. Combined chemokine and cytokine gene transfer enhances antitumor immunity. Nat Med. 1996;2:1090–1095.CrossRefPubMedGoogle Scholar
  46. 46.
    Cignetti A et al. Transduction of the IL2 gene into human acute leukemia cells: induction of tumor rejection without modifying cell proliferation and IL2 receptor expression. J Natl Cancer Inst. 1994;86:785–791.CrossRefPubMedGoogle Scholar
  47. 47.
    Nishimura T et al. The application of IL-12 to cytokine therapy and gene therapy for tumors. Ann N Y Acad Sci. 1996;795:375–378.CrossRefPubMedGoogle Scholar
  48. 48.
    Nishimura, T et al. Application of interleukin 12 to antitumor cytokine and gene therapy. Cancer Chemother Pharmacol. 1996;38 Suppl:S27–S34.Google Scholar
  49. 49.
    Dunussi-Joannopoulos K et al. Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines. Blood. 1998;91:222–230.PubMedGoogle Scholar
  50. 50.
    Stripecke R et al. Immune response to Philadelphia chromosome-positive acute lymphoblastic leukemia induced by expression of CD80, interleukin 2, and granulocyte-macrophage colony-stimulating factor. Hum Gene Ther. 1998;9:2049–2062.CrossRefPubMedGoogle Scholar
  51. 51.
    Stripecke R et al. Combination of CD80 and granulocyte-macrophage colony-stimulating factor coexpression by a leukemia cell vaccine: preclinical studies in a murine model recapitulating Philadelphia chromosome-positive acute lymphoblastic leukemia. Hum Gene Ther. 1999;10:2109–2122.CrossRefPubMedGoogle Scholar
  52. 52.
    Stam AG et al. CD40-targeted adenoviral GM-CSF gene transfer enhances and prolongs the maturation of human CML-derived dendritic cells upon cytokine deprivation. Br J Cancer. 2003;89:1162–1165.CrossRefPubMedGoogle Scholar
  53. 53.
    Stripecke R et al. Lentiviral vectors for efficient delivery of CD80 and granulocyte-macrophage- colony-stimulating factor in human acute lymphoblastic leukemia and acute myeloid leukemia cells to induce antileukemic immune responses. Blood. 2000;96:1317–1326.PubMedGoogle Scholar
  54. 54.
    Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA. 1993;90:3539–3543.CrossRefPubMedGoogle Scholar
  55. 55.
    Abe J et al. Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol. 1995;121:587–592.CrossRefPubMedGoogle Scholar
  56. 56.
    Gautam SC et al. Antileukemic activity of TNF-alpha gene therapy with myeloid progenitor cells against minimal leukemia. J Hematother. 1998;7:115–125.PubMedGoogle Scholar
  57. 57.
    Gautam SC et al. TNF-alpha gene therapy with myeloid progenitor cells lacks the toxicities of systemic TNF-alpha therapy. J Hematother. 1999;8:237–245.CrossRefPubMedGoogle Scholar
  58. 58.
    Xu YX et al. In vitro analysis of the antileukemic effect of tumor necrosis factor-alpha gene therapy with myeloid progenitor cells: the role of dendritic cells. J Exp Ther Oncol. 2003;3:62–71.CrossRefPubMedGoogle Scholar
  59. 59.
    Deeb D et al. Vaccination with leukemia-loaded dendritic cells eradicates residual disease and prevent relapse. J Exp Ther Oncol. 2006;5:183–193.PubMedGoogle Scholar
  60. 60.
    Lanier LL et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J Immunol. 1995;154:97–105.PubMedGoogle Scholar
  61. 61.
    Matulonis U et al. B7–1 is superior to B7–2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7–1 and B7–2 are functionally distinct. J Immunol. 1996;156:1126–1131.PubMedGoogle Scholar
  62. 62.
    Wendtner CM et al. Gene transfer of the costimulatory molecules B7–1 and B7–2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response. Gene Ther. 1997;4:726–735.CrossRefPubMedGoogle Scholar
  63. 63.
    Hirst WJ et al. Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1. Gene Ther. 1997;4:691–699.CrossRefPubMedGoogle Scholar
  64. 64.
    Mutis T, Schrama E, Melief CJ, Goulmy E. CD80-Transfected acute myeloid leukemia cells induce primary allogeneic T-cell responses directed at patient specific minor histocompatibility antigens and leukemia-associated antigens. Blood. 1998;92:1677–1684.PubMedGoogle Scholar
  65. 65.
    Koya RC et al. Transduction of acute myeloid leukemia cells with third generation self-inactivating lentiviral vectors expressing CD80 and GM-CSF: effects on proliferation, differentiation, and stimulation of allogeneic and autologous anti-leukemia immune responses. Leukemia. 2002;16:1645–1654.CrossRefPubMedGoogle Scholar
  66. 66.
    Chan L et al. IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML. Mol Ther. 2005;11:120–131.CrossRefPubMedGoogle Scholar
  67. 67.
    Vereecque R et al. Gene transfer of GM-CSF, CD80 and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of a minimal residual disease. Gene Ther. 2000;7:1312–1316.CrossRefPubMedGoogle Scholar
  68. 68.
    Briones J, Timmerman JM, Panicalli DL, Levy R. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules. J Natl Cancer Inst. 2003;95:548–555.CrossRefPubMedGoogle Scholar
  69. 69.
    Palena C et al. Potential approach to immunotherapy of chronic lymphocytic leukemia (CLL): enhanced immunogenicity of CLL cells via infection with vectors encoding for multiple costimulatory molecules. Blood. 2005;106:3515–3523.CrossRefPubMedGoogle Scholar
  70. 70.
    Ranheim EA, Kipps TJ. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med. 1993;177:925–935.CrossRefPubMedGoogle Scholar
  71. 71.
    Cantwell M, Hua T, Pappas J, Kipps TJ. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med. 1997;3:984–989.CrossRefPubMedGoogle Scholar
  72. 72.
    Eshhar Z. Tumor-specific T-bodies: towards clinical application. Cancer Immunol Immunother. 1997;45:131–136.CrossRefPubMedGoogle Scholar
  73. 73.
    Wang J et al. Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes. Mol Ther. 2004;9:577–586.CrossRefPubMedGoogle Scholar
  74. 74.
    Dembic Z et al. Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature. 1986;320:232–238.CrossRefPubMedGoogle Scholar
  75. 75.
    Ohashi PS et al. Reconstitution of an active surface T3/T-cell antigen receptor by DNA transfer. Nature. 1985;316:606–609.CrossRefPubMedGoogle Scholar
  76. 76.
    Clay TM et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol. 1999;163:507–513.PubMedGoogle Scholar
  77. 77.
    Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther. 2004;10:5–18.CrossRefPubMedGoogle Scholar
  78. 78.
    Orentas RJ, Roskopf SJ, Nolan GP, Nishimura MI. Retroviral transduction of a T cell receptor specific for an Epstein-Barr virus-encoded peptide. Clin Immunol. 2001;98:220–228.CrossRefPubMedGoogle Scholar
  79. 79.
    Cooper LJ et al. Transfer of specificity for human immunodeficiency virus type 1 into primary human T lymphocytes by introduction of T-cell receptor genes. J Virol. 2000;74:8207–8212.CrossRefPubMedGoogle Scholar
  80. 80.
    Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med. 2001;7:1118–1122.CrossRefPubMedGoogle Scholar
  81. 81.
    Bollard CM et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity. Blood. 2002;99:3179–3187.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Xiaopei Huang
    • 1
  • Yiping Yang
    • 1
  1. 1.Department of Medicine and ImmunologyDuke University Medical CenterDurhamUSA

Personalised recommendations